Gustave Roussy highly represented at ASCO 2016
At this 52nd annual meeting of the world’s most important oncology conference, Gustave Roussy confirms its leading role in the development of three therapeutic strategies that are changing practice and transforming patient treatment:
- Immunotherapy is extending its application to new pathologies
- Precision medicine are becoming routine therapeutic options, as monotherapy or in combination
- Optimisation of chemotherapies
In addition, on Sunday 5th June, Dr Dominique Valteau-Couannet, Head of the Gustave Roussy Paediatric Department, will be a discussant in a plenary session of childhood neuroblastoma treatment about the optimisation of existing treatments.
This year, Gustave Roussy medical researchers present their work in a total of 75 sessions. The ASCO Scientific Committee has selected 21 oral communications, 6 of which will be delivered by doctors from the Institute; 11 poster-discussions, 6 of which are to be presented by Gustave Roussy researchers; and 42 posters and 1 educational session authored by doctor researchers from the Institute.
More information: